AR037687A1 - Composiciones farmaceuticas a base de derivados de azetidina - Google Patents
Composiciones farmaceuticas a base de derivados de azetidinaInfo
- Publication number
- AR037687A1 AR037687A1 ARP020104646A ARP020104646A AR037687A1 AR 037687 A1 AR037687 A1 AR 037687A1 AR P020104646 A ARP020104646 A AR P020104646A AR P020104646 A ARP020104646 A AR P020104646A AR 037687 A1 AR037687 A1 AR 037687A1
- Authority
- AR
- Argentina
- Prior art keywords
- azetidine
- derivative
- general formula
- pharmaceutical compositions
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Composición farmacéutica estable, que comprende al menos un derivado de azetidina de fórmula general (ia) o (ib) en la que Ar es un grupo aromático o heteroaromático, eventualmente substituido por uno o varios alquilo ( con 1 a 4 átomos de carbono ), halógeno, NO2, CN, alcoxi ( con 1 a 4 átomos de carbono ) o OH, eventualmente en asociación con otro principio activo, capaz de potencializar los efectos del derivado de azetidina de fórmula general (ia) o (ib), en un sistema que comprende como máximo dos excipientes principales elegidos entre un agente tensioactivo no iónico de carácter hidrófilo, capas de solubilizar el derivado de azetidina de fórmula general (ia) o (ib) y, en caso dado, el principio activo que potencializa los efectos del derivado de azetidina, y capaz de provocar la formación de un sistema coloidal, combinado, eventualmente, con un segundo excipiente de naturaleza lipófila, que estabilice la formulación. Las composiciones farmacéuticas, que comprenden derivados de azetidina de las fórmulas (ia) o (ib), son particularmente interesantes, debido a la fuerte afinadad de estos derivados para los receptores cannabinoides.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0116638A FR2833842B1 (fr) | 2001-12-21 | 2001-12-21 | Compositions pharmaceutiques a base de derives d'azetidine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037687A1 true AR037687A1 (es) | 2004-12-01 |
Family
ID=8870824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020104646A AR037687A1 (es) | 2001-12-21 | 2002-12-02 | Composiciones farmaceuticas a base de derivados de azetidina |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP1458413B1 (es) |
| JP (1) | JP5021887B2 (es) |
| KR (1) | KR20040068308A (es) |
| CN (1) | CN100388918C (es) |
| AP (1) | AP1754A (es) |
| AR (1) | AR037687A1 (es) |
| AU (1) | AU2002364866B2 (es) |
| BR (1) | BR0215048A (es) |
| CA (1) | CA2470443A1 (es) |
| CO (1) | CO5590911A2 (es) |
| DE (1) | DE60233071D1 (es) |
| DK (1) | DK1458413T3 (es) |
| EA (1) | EA006510B1 (es) |
| EC (1) | ECSP045162A (es) |
| FR (1) | FR2833842B1 (es) |
| HK (1) | HK1070840A1 (es) |
| HR (1) | HRP20040575A2 (es) |
| HU (1) | HUP0402586A3 (es) |
| IL (1) | IL162563A0 (es) |
| MA (1) | MA27086A1 (es) |
| ME (1) | MEP16608A (es) |
| MX (1) | MXPA04005558A (es) |
| MY (1) | MY138172A (es) |
| NO (1) | NO20042781L (es) |
| NZ (1) | NZ533225A (es) |
| OA (1) | OA12750A (es) |
| PL (1) | PL203248B1 (es) |
| RS (1) | RS55504A (es) |
| TW (1) | TWI256304B (es) |
| UA (1) | UA77736C2 (es) |
| WO (1) | WO2003053431A2 (es) |
| ZA (1) | ZA200404338B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1498122A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Semi-solid systems containing azetidine derivatives |
| EP1498123A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Emulsifying systems containing azetidine derivatives |
| CA2556565A1 (en) | 2004-02-17 | 2005-08-25 | Laboratorios Del Dr. Esteve S.A. | Substituted azetidine compounds, their preparation and use as medicaments |
| FR2879932B1 (fr) * | 2004-12-27 | 2007-03-23 | Aventis Pharma Sa | Formulations injectable ou administrable par voie orale de derives d'azetidine |
| CA2613235A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
| AR064735A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr y composicion farmaceutica en base al compuesto |
| PE20081849A1 (es) | 2007-01-04 | 2009-01-26 | Prosidion Ltd | Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr |
| GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
| BRPI0806312A2 (pt) | 2007-01-04 | 2011-09-06 | Prosidion Ltd | agonistas cgpr piperidina |
| EP2377863A1 (en) | 2007-01-04 | 2011-10-19 | Prosidion Limited | Piperidine GPCR agonists |
| GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
| FR2923719B1 (fr) * | 2007-11-15 | 2009-11-20 | Sanofi Aventis | Compositions pharmaceutiques a base de derives d'azetidine |
| FR2928149B1 (fr) | 2008-02-29 | 2011-01-14 | Sanofi Aventis | Composes derives d'azetidines, leur preparation et leur application en therapeutique |
| FR2946650B1 (fr) * | 2009-06-16 | 2011-08-19 | Sanofi Aventis | Esters derives d'azetidines, leur preparation et leur application en therapeutique. |
| UA153183U (uk) | 2022-10-27 | 2023-05-31 | Андрій Валерійович Максимов | Стаканчик для приготування напою |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR73668B (es) * | 1978-11-21 | 1984-03-28 | Hoffmann La Roche | |
| US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| HRP980026A2 (en) * | 1998-01-20 | 1999-10-31 | Pliva Pharm & Chem Works | 1-izothiazolydinone derivatives of azetidine-2-ones, processes for the preparation and use thereof |
| CA2302735A1 (en) * | 1998-07-14 | 2000-01-27 | Em Industries, Inc. | Microdisperse drug delivery systems |
| FR2783246B1 (fr) * | 1998-09-11 | 2000-11-17 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les medicaments les contenant |
| FR2805817B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
| FR2805818B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
| FR2805810B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation |
| FR2814678B1 (fr) * | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite |
-
2001
- 2001-12-21 FR FR0116638A patent/FR2833842B1/fr not_active Expired - Fee Related
-
2002
- 2002-12-02 AR ARP020104646A patent/AR037687A1/es unknown
- 2002-12-03 TW TW091135077A patent/TWI256304B/zh active
- 2002-12-20 PL PL372708A patent/PL203248B1/pl not_active IP Right Cessation
- 2002-12-20 CA CA002470443A patent/CA2470443A1/fr not_active Abandoned
- 2002-12-20 EP EP02801165A patent/EP1458413B1/fr not_active Expired - Lifetime
- 2002-12-20 UA UA20040706001A patent/UA77736C2/uk unknown
- 2002-12-20 OA OA1200400178A patent/OA12750A/fr unknown
- 2002-12-20 AP APAP/P/2004/003066A patent/AP1754A/en active
- 2002-12-20 WO PCT/FR2002/004514 patent/WO2003053431A2/fr active IP Right Grant
- 2002-12-20 IL IL16256302A patent/IL162563A0/xx unknown
- 2002-12-20 DK DK02801165T patent/DK1458413T3/da active
- 2002-12-20 CN CNB028248406A patent/CN100388918C/zh not_active Expired - Fee Related
- 2002-12-20 AU AU2002364866A patent/AU2002364866B2/en not_active Ceased
- 2002-12-20 EA EA200400843A patent/EA006510B1/ru not_active IP Right Cessation
- 2002-12-20 DE DE60233071T patent/DE60233071D1/de not_active Expired - Lifetime
- 2002-12-20 HU HU0402586A patent/HUP0402586A3/hu unknown
- 2002-12-20 MX MXPA04005558A patent/MXPA04005558A/es active IP Right Grant
- 2002-12-20 RS YUP-555/04A patent/RS55504A/sr unknown
- 2002-12-20 ME MEP-166/08A patent/MEP16608A/xx unknown
- 2002-12-20 MY MYPI20024828A patent/MY138172A/en unknown
- 2002-12-20 BR BR0215048-4A patent/BR0215048A/pt not_active IP Right Cessation
- 2002-12-20 KR KR10-2004-7009708A patent/KR20040068308A/ko not_active Application Discontinuation
- 2002-12-20 NZ NZ533225A patent/NZ533225A/en not_active IP Right Cessation
- 2002-12-20 JP JP2003554188A patent/JP5021887B2/ja not_active Expired - Fee Related
-
2004
- 2004-05-21 MA MA27694A patent/MA27086A1/fr unknown
- 2004-06-02 ZA ZA200404338A patent/ZA200404338B/en unknown
- 2004-06-17 CO CO04056913A patent/CO5590911A2/es not_active Application Discontinuation
- 2004-06-18 EC EC2004005162A patent/ECSP045162A/es unknown
- 2004-06-18 HR HR20040575A patent/HRP20040575A2/hr not_active Application Discontinuation
- 2004-07-01 NO NO20042781A patent/NO20042781L/no not_active Application Discontinuation
-
2005
- 2005-05-04 HK HK05103765A patent/HK1070840A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR037687A1 (es) | Composiciones farmaceuticas a base de derivados de azetidina | |
| AR037951A1 (es) | Composiciones farmaceuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada | |
| BRPI0416752B8 (pt) | composição farmacêutica, uso de um ou mais compostos, e, compostos | |
| PE20071243A1 (es) | Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceutica y un conjunto (kit) para la preparacion de una formulacion inyectable de taxano | |
| CO5640125A2 (es) | Composicion inhibidora selectiva de la ciclooxigenasa-2 permeable en la piel | |
| BRPI0508540A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| CY1106522T1 (el) | Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο | |
| NO20000466L (no) | Farmasøytisk preparat for sure, lipofile forbindelser i form av en selvregulerende formulering | |
| AR099754A2 (es) | Composición farmacéutica agonista de subtipo de receptor 5-ht₁a | |
| BRPI0518484A2 (pt) | composiÇço, cÁpsula, e, processo para preparar a mesma | |
| CO5580835A2 (es) | Nuevas formulaciones analogas de ciclosporina | |
| ECSP014097A (es) | Derivados de tiofeno utiles como agentes anticancerosos | |
| AR036248A1 (es) | Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica | |
| CY1108676T1 (el) | Οφθαλμικο εναιωρημα περιλαμβανον ενα οφθαλμικο φαρμακο, μια πολοξαμινη και εναν παραγοντα ρυθμισεως της τονικοτητας τυπου γλυκολης, χρηση της εν λογω συνθεσεως για την παραγωγη ενος φαρμακου για την αγωγη οφθαλμικων διαταραχων | |
| PA8495101A1 (es) | Derivados de 13-metileritromicina | |
| SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
| BRPI0417161A (pt) | compostos, composições farmacêuticas, e, uso de um composto | |
| CO5540294A2 (es) | Una combinacion de un derivado de rapamicina y un agente alquilante seleccionado de ciclofosfamida y carmustina y composiciones que las contienen | |
| AR045912A1 (es) | Composiciones farmaceuticas que contienen derivados de azetidina | |
| JP5052028B2 (ja) | アシタザノラスト含有組成物 | |
| AR045911A1 (es) | Formulaciones auto-emulsionables y formulaciones auto-microemulsionables para la administracion oral de taxoides | |
| BR0312817A (pt) | Composição de pomada oftálmica compreendendo uma droga, uma base de pomada e um agente solubilizante/dispersante | |
| BRPI0414494A (pt) | compostos, composições farmacêuticas, e, uso de um composto | |
| BR0212744A (pt) | Formulações de cisplatina de toxicidade reduzida e métodos para uso das mesmas | |
| PE20060743A1 (es) | Formulaciones inyectables o administrables por via oral de derivados de azetidina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |